Is Zepbound supposed to work immediately?
Initial loss often appears in 2-4 weeks; substantial loss requires titration to higher doses.
What if I lost weight then stopped?
Could be dose plateau, biological plateau, or eating shift; each has different intervention.
How much should I lose on Zepbound?
SURMOUNT-1 means: 15.0% at 5 mg, 19.5% at 10 mg, 22.5% at 15 mg over 72 weeks.
Can I take Zepbound forever?
SURMOUNT-4 supports long-term continuation for maintenance; many patients do.
Should I exercise?
Yes, especially resistance training for muscle preservation.
What if my dose was reduced?
Progress may slow; discuss re-titration timing with your prescriber.
Could I be a non-responder?
About 14% of SURMOUNT-1 participants lost less than 5%; biological variation is real.
Does perimenopause affect results?
Yes; hormonal transitions affect weight regulation; coordinated care helps.
When should I be concerned?
After 16+ weeks at a therapeutic dose without measurable progress.
Related guides
- Why Am I Not Losing Weight on Mounjaro? Plateau Patterns and Real Causes
- Why Am I Gaining Weight on Semaglutide? Causes and Course Correction
- Stopped Losing Weight on Ozempic? Plateau-After-Loss Patterns Explained
- Why Am I Not Losing Weight on Ozempic? The Six Causes Worth Investigating
- Why Am I Not Losing Weight on Wegovy? The Six Levers Worth Pulling
- Why Am I Not Losing Weight on Semaglutide? Brand and Compounded Considerations
Sources
- Jastreboff AM et al., "Tirzepatide Once Weekly for the Treatment of Obesity," NEJM, July 2022 (SURMOUNT-1)
- Aronne LJ et al., SURMOUNT-4, JAMA, January 2024
- Zepbound FDA prescribing information
- Mounjaro FDA prescribing information
- Wilding JPH et al., STEP 1, NEJM 2021
- Tasali E et al., JAMA Internal Medicine, March 2022
- Endocrine Society Clinical Practice Guideline on Obesity, 2023
- NAMS (North American Menopause Society) position statements on weight in menopause
- American Thyroid Association screening guidelines
- ACSM resistance training guidelines for adults
- CDC alcohol use guidelines
- American College of Endocrinology obesity consensus statements
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians for evaluation and management. This article is educational. Clinical decisions about Zepbound therapy involve individual assessment by your prescriber.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Compounded Medication Notice. Compounded tirzepatide is available through 503A pharmacy partners for patients with documented clinical justification. Not FDA-approved. SURMOUNT trial data applies to brand Zepbound and Mounjaro specifically.
Results Disclaimer. Outcomes vary substantially across individuals. SURMOUNT-1 means represent group averages with wide distribution; individual results depend on dose, adherence, baseline, lifestyle, and physiology.
Trademark Notice. Zepbound, Mounjaro, SURMOUNT, and LillyDirect are trademarks or service marks of Eli Lilly and Company. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →